Skip to main content
PMC home page
Journal of Medical Ethics logoLink to Journal of Medical Ethics
. 2005 Apr;31(4):209–214. doi: 10.1136/jme.2003.006247

Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis

J Kimmelman 1, N Palmour 1
PMCID: PMC1734123  PMID: 15800361

Abstract

Background: "Therapeutic misconception" arises when human subjects interpret a clinical trial as aimed primarily at therapy rather than producing knowledge. Therapeutic misconceptions may be more prevalent in trials enrolling gravely ill subjects or involving novel and well publicised investigational agents.

Objective: To examine the extent to which investigators express therapeutic optimism in phase 1 human gene transfer consent documents, whether highly active gene transfer researchers are more prone to expressing therapeutic optimism, and whether consent forms have grown more optimistic in their descriptions of personal benefit over the last decade.

Design: Content analysis was performed on 277 consent documents to measure the number of sentences describing possibility of benefit, terminology used for experimental agents, the proportion of statements describing personal versus societal benefits, and whether investigators attempted to thwart therapeutic misconceptions.

Results: Consent forms generally used therapeutic terminology to describe study agents, devoted more sentences to describing possible personal benefits than to describing benefits to society, and infrequently explained that a particular benefit was unlikely. Consent documents used by highly active gene transfer researchers tended to portray significantly greater optimism about personal benefit than less active investigators, though they were also significantly more cautious with agent terminology. Finally, therapeutic optimism expressed in consent forms has declined over the past decade.

Conclusions: Consent documents used in phase 1 gene transfer trials, although increasingly attentive to possible therapeutic misconceptions, are inappropriately optimistic about direct benefits of trial participation. Such optimism is expressed more emphatically in trials involving highly active gene transfer researchers as principal investigators.

Full Text

The Full Text of this article is available as a PDF (95.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. S., Roth L. H., Lidz C. W., Benson P., Winslade W. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep. 1987 Apr;17(2):20–24. [PubMed] [Google Scholar]
  2. Churchill L. R., Collins M. L., King N. M., Pemberton S. G., Wailoo K. A. Genetic research as therapy: implications of "gene therapy" for informed consent. J Law Med Ethics. 1998 Spring;26(1):38-47, 3. doi: 10.1111/j.1748-720x.1998.tb01904.x. [DOI] [PubMed] [Google Scholar]
  3. Daugherty C., Ratain M. J., Grochowski E., Stocking C., Kodish E., Mick R., Siegler M. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995 May;13(5):1062–1072. doi: 10.1200/JCO.1995.13.5.1062. [DOI] [PubMed] [Google Scholar]
  4. Decoster G., Stein G., Holdener E. E. Responses and toxic deaths in phase I clinical trials. Ann Oncol. 1990;1(3):175–181. doi: 10.1093/oxfordjournals.annonc.a057716. [DOI] [PubMed] [Google Scholar]
  5. Estey E., Hoth D., Simon R., Marsoni S., Leyland-Jones B., Wittes R. Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep. 1986 Sep;70(9):1105–1115. [PubMed] [Google Scholar]
  6. Henderson Gail E., Davis Arlene M., King Nancy M. P., Easter Michele M., Zimmer Catherine R., Rothschild Barbra Bluestone, Wilfond Benjamin S., Nelson Daniel K., Churchill Larry R. Uncertain benefit: investigators' views and communications in early phase gene transfer trials. Mol Ther. 2004 Aug;10(2):225–231. doi: 10.1016/j.ymthe.2004.05.013. [DOI] [PubMed] [Google Scholar]
  7. Horng Sam, Emanuel Ezekiel J., Wilfond Benjamin, Rackoff Jonathan, Martz Karen, Grady Christine. Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med. 2002 Dec 26;347(26):2134–2140. doi: 10.1056/NEJMsa021182. [DOI] [PubMed] [Google Scholar]
  8. Howard J., Friedman L. Protecting the scientific integrity of a clinical trial: some ethical dilemmas. Clin Pharmacol Ther. 1981 May;29(5):561–569. doi: 10.1038/clpt.1981.78. [DOI] [PubMed] [Google Scholar]
  9. Joffe S., Cook E. F., Cleary P. D., Clark J. W., Weeks J. C. Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet. 2001 Nov 24;358(9295):1772–1777. doi: 10.1016/S0140-6736(01)06805-2. [DOI] [PubMed] [Google Scholar]
  10. Kent G. Shared understandings for informed consent: the relevance of psychological research on the provision of information. Soc Sci Med. 1996 Nov;43(10):1517–1523. doi: 10.1016/0277-9536(96)00173-6. [DOI] [PubMed] [Google Scholar]
  11. King N. M. Defining and describing benefit appropriately in clinical trials. J Law Med Ethics. 2000 Winter;28(4):332–343. doi: 10.1111/j.1748-720x.2000.tb00685.x. [DOI] [PubMed] [Google Scholar]
  12. King N. M. Experimental treatment. Oxymoron or aspiration? Hastings Cent Rep. 1995 Jul-Aug;25(4):6–15. [PubMed] [Google Scholar]
  13. Kodish E., Stocking C., Ratain M. J., Kohrman A., Siegler M. Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons. J Clin Oncol. 1992 Nov;10(11):1810–1816. doi: 10.1200/JCO.1992.10.11.1810. [DOI] [PubMed] [Google Scholar]
  14. Levine R. J. Ethics of clinical trials. Do they help the patient? Cancer. 1993 Nov 1;72(9 Suppl):2805–2810. doi: 10.1002/1097-0142(19931101)72:9+<2805::aid-cncr2820721506>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  15. Levine R. J. The impact of HIV infection on society's perception of clinical trials. Kennedy Inst Ethics J. 1994 Jun;4(2):93–98. doi: 10.1353/ken.0.0054. [DOI] [PubMed] [Google Scholar]
  16. Levinsky Norman G. Nonfinancial conflicts of interest in research. N Engl J Med. 2002 Sep 5;347(10):759–761. doi: 10.1056/NEJMsb020853. [DOI] [PubMed] [Google Scholar]
  17. Lipsett M. B. On the nature and ethics of phase I clinical trials of cancer chemotherapies. JAMA. 1982 Aug 27;248(8):941–942. [PubMed] [Google Scholar]
  18. Madsen S. M., Mirza M. R., Holm S., Hilsted K. L., Kampmann K., Riis P. Attitudes towards clinical research amongst participants and nonparticipants. J Intern Med. 2002 Feb;251(2):156–168. doi: 10.1046/j.1365-2796.2002.00949.x. [DOI] [PubMed] [Google Scholar]
  19. Miller M. Phase I cancer trials. A collusion of misunderstanding. Hastings Cent Rep. 2000 Jul-Aug;30(4):34–43. [PubMed] [Google Scholar]
  20. Penman D. T., Holland J. C., Bahna G. F., Morrow G., Schmale A. H., Derogatis L. R., Carnrike C. L., Jr, Cherry R. Informed consent for investigational chemotherapy: patients' and physicians' perceptions. J Clin Oncol. 1984 Jul;2(7):849–855. doi: 10.1200/JCO.1984.2.7.849. [DOI] [PubMed] [Google Scholar]
  21. Schaeffer M. H., Krantz D. S., Wichman A., Masur H., Reed E., Vinicky J. K. The impact of disease severity on the informed consent process in clinical research. Am J Med. 1996 Mar;100(3):261–268. doi: 10.1016/S0002-9343(97)89483-1. [DOI] [PubMed] [Google Scholar]
  22. Snowdon C., Garcia J., Elbourne D. Making sense of randomization; responses of parents of critically ill babies to random allocation of treatment in a clinical trial. Soc Sci Med. 1997 Nov;45(9):1337–1355. doi: 10.1016/s0277-9536(97)00063-4. [DOI] [PubMed] [Google Scholar]
  23. Sugarman Jeremy, Kass Nancy E., Goodman Steven N., Perentesis Patricia, Fernandes Praveen, Faden Ruth R. What patients say about medical research. IRB. 1998 Jul-Aug;20(4):1–7. [PubMed] [Google Scholar]
  24. Von Hoff D. D., Turner J. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs. 1991 Feb;9(1):115–122. doi: 10.1007/BF00194562. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Ethics are provided here courtesy of BMJ Publishing Group

RESOURCES